Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.

@article{Curet1998PreclinicalPO,
  title={Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.},
  author={Olivier Curet and G Damoiseau-Ovens and Claude Sauvage and Nicole Sontag and Patrick Avenet and Henri Depoortere and Dominique Caille and Olivier E. Bergis and Bernard Scatton},
  journal={Journal of affective disorders},
  year={1998},
  volume={51 3},
  pages={287-303}
}
Befloxatone, a novel oxazolidinone derivative, is a potent, selective and reversible monoamine oxidase A (MAO-A) inhibitor in vitro (K1A = 1.9-3.6 nM) and ex vivo (ED50 MAO-A = 0.02 mg/kg, p.o.). It does not interact with a large number of receptors, monoamine transporters or other amine oxidases. Binding studies with [3H]-befloxatone in rat brain sections show that it labels with high affinity (Kd = 1.3 nM) a single population of sites with the pharmacological characteristics and regional… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…